SCHEMBL12501422

SCHEMBL12501422

CN(C)C=CC(=O)c1cccc(F)n1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.57
RECQL P46063 2/20 0.53
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
ALDH1A1 P00352 8/20 0.49
MAPT P10636 8/20 0.49
HTT P42858 5/20 0.49
GAA P10253 4/20 0.49
HPGD P15428 3/20 0.49
RAB9A P51151 5/20 0.44
LMNA P02545 3/20 0.42
ALOX12 P18054 1/20 0.42
POLB P06746 4/20 0.42
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30046046 0.88 RECQL (0.61) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL23251391 0.88 RECQL (0.61) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL4782704 0.82 RECQL (0.54) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL11363955 0.82 RECQL (0.54) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL14733065 0.81 RECQL (0.53) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL12501360 0.78 RECQL (0.50) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL5348329 0.75 GRM4 (0.40) TDP1CYP1A2ALDH1A1
SCHEMBL30703596 0.74 TDP1 (0.53) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL20090329 0.74 TDP1 (0.53) TDP1RECQLCYP1A2CYP2C19ALDH1A1
SCHEMBL30328012 0.74 GRM4 (0.41) TDP1RECQLCYP1A2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668177-B1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2014-10-22 EP disclosed
US-8772305-B2 Substituted pyridinyl-pyrimidines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 US disclosed
EP-2668177-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2013-12-04 EP disclosed
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-24 US disclosed
WO-2012101013-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS ADORA1, P2RY1, P2RY11 TDP1 1880/4885RECQL 108/4885CYP1A2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.